<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Terapevticheskii arkhiv</journal-id><journal-title-group><journal-title xml:lang="en">Terapevticheskii arkhiv</journal-title><trans-title-group xml:lang="ru"><trans-title>Терапевтический архив</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0040-3660</issn><issn publication-format="electronic">2309-5342</issn><publisher><publisher-name xml:lang="en">LLC Obyedinennaya Redaktsiya</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">71512</article-id><article-id pub-id-type="doi">10.26442/00403660.2021.05.200790</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Original articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Оригинальные статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Vitamin D status in women with rheumatoid arthritis: frequency of hypovitaminosis, associations with disease activity, body composition and comorbidity</article-title><trans-title-group xml:lang="ru"><trans-title>Статус витамина D у женщин с ревматоидным артритом: частота гиповитаминоза, связь с активностью заболевания, композиционным составом тела и коморбидностью</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2809-0197</contrib-id><name-alternatives><name xml:lang="en"><surname>Dobrovolskaya</surname><given-names>Olga V.</given-names></name><name xml:lang="ru"><surname>Добровольская</surname><given-names>Ольга Валерьевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>канд. мед. наук, науч. сотр. лаб. остеопороза</p></bio><email>olgavdobr@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4739-4302</contrib-id><name-alternatives><name xml:lang="en"><surname>Toroptsova</surname><given-names>Natalia V.</given-names></name><name xml:lang="ru"><surname>Торопцова</surname><given-names>Наталья Владимировна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>д-р мед. наук, зав. лаб. остеопороза</p></bio><email>torop@irramn.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6759-8367</contrib-id><name-alternatives><name xml:lang="en"><surname>Nikitinskaya</surname><given-names>Oksana A.</given-names></name><name xml:lang="ru"><surname>Никитинская</surname><given-names>Оксана Анатольевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>канд. мед. наук, ст. науч. сотр. лаб. остеопороза</p></bio><email>nikitinskaya@niir.su</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7501-9185</contrib-id><name-alternatives><name xml:lang="en"><surname>Samarkina</surname><given-names>Elena Y.</given-names></name><name xml:lang="ru"><surname>Самаркина</surname><given-names>Елена Юрьевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>мл. науч. сотр. лаб. иммунологии и молекулярной биологии ревматических заболеваний</p></bio><email>epid@irramn.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3246-1157</contrib-id><name-alternatives><name xml:lang="en"><surname>Cherkasova</surname><given-names>Mariia V.</given-names></name><name xml:lang="ru"><surname>Черкасова</surname><given-names>Мария Владимировна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>канд. биол. наук, зав. лаб. иммунологии и молекулярной биологии ревматических заболеваний</p></bio><email>epid@irramn.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7661-3124</contrib-id><name-alternatives><name xml:lang="en"><surname>Feklistov</surname><given-names>Aleksei Y.</given-names></name><name xml:lang="ru"><surname>Феклистов</surname><given-names>Алексей Юрьевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>мл. науч. сотр. лаб. остеопороза</p></bio><email>epid@irramn.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Nasonova Research Institute of Rheumatology</institution></aff><aff><institution xml:lang="ru">ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2021-05-15" publication-format="electronic"><day>15</day><month>05</month><year>2021</year></pub-date><volume>93</volume><issue>5</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>581</fpage><lpage>586</lpage><history><date date-type="received" iso-8601-date="2021-06-12"><day>12</day><month>06</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2021-06-12"><day>12</day><month>06</month><year>2021</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2021, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2021, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://ter-arkhiv.ru/0040-3660/article/view/71512">https://ter-arkhiv.ru/0040-3660/article/view/71512</self-uri><abstract xml:lang="en"><p><bold>Aim. </bold>To evaluate the status of vitamin D in women with rheumatoid arthritis (RA) and establish its associations with comorbidity, disease activity, and body composition components.</p> <p><bold>Materials and methods</bold>. 86 women with RA (average age 58.1±8.5 years) were enrolled in the study. We analyzed the relationship of vitamin D levels with clinical and laboratory parameters and with the results of two-energy x-ray absorptiometry. Mann–Whitney or Kruskal–Wallis, χ<sup>2</sup> and Spearman tests were performed using Statistica for Windows 10.0 (StatSoft Inc., USA).</p> <p><bold>Results. </bold>Vitamin D level was 22.4 [17.8; 27.3] ng/ml: deficiency was detected in 33%, and insufficiency – in 46% of women with RA. Only 41% of patients with low vitamin D levels received supplements of cholecalciferol, while only 9% – in a sufficient dose. 25(OH)D level was significantly lower in RA patients with sarcopenia, obesity, high activity according to DAS28 and in those who did not receive vitamin D supplements. There weren’t differences in 25(OH)D levels among subgroups of patient according to age, fertility, BMD status, comorbidity index, RA duration, ESR and CRP levels, medical therapy performed.</p> <p><bold>Conclusion.</bold> 79% of patients with RA had low levels of vitamin D, while less than half of them received additional cholecalciferol supplements. Low vitamin D levels in RA patients were associated with high disease activity, sarcopenia, and obesity.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Цель.</bold> Оценить статус витамина D у женщин с ревматоидным артритом (РА) и установить его ассоциации с коморбидностью, активностью заболевания и компонентами состава тела.</p> <p><bold>Материалы и методы. </bold>В исследование включены 86 женщин с РА, средний возраст 58,1±8,5 года. Проведены анкетирование, денситометрическое и лабораторное обследование. Проанализирована связь уровня витамина D c клинико-анамнестическими, лабораторными данными и результатами денситометрии. Анализ выполнен с использованием U-теста Манна–Уитни или критерия Краскела–Уоллиса, метода χ<sup>2</sup> и корреляционного анализа по Спирмену с помощью пакета Statistica for Windows 10.0 (StatSoft Inc., USA).</p> <p><bold>Результаты. </bold>Уровень витамина D составил 22,4 [17,8; 27,3] нг/мл, дефицит выявлен у 33%, а недостаточность – у 46% женщин с РА. Только 41% пациентов из числа лиц с низким уровнем 25(ОН)D дополнительно принимали колекальциферол, при этом лишь 9% – в достаточной дозе. Уровень 25(ОН)D значимо ниже у больных РА с саркопенией, ожирением, высокой активностью по DAS28, а также у лиц, не получавших дополнительно препараты витамина D, в то же время не выявлено различий в зависимости от возраста, фертильности, состояния минеральной плотности кости, индекса коморбидности, длительности РА, показателей скорости оседания эритроцитов и С-реактивного белка, характера проводимой терапии.</p> <p><bold>Заключение. </bold>Низкий уровень витамина D имели 79% пациентов с РА, в то же время менее 1/2 из них получали дополнительно колекальциферол. Низкий уровень витамина D ассоциировался с наличием у них высокой активности заболевания, саркопенией и ожирением.</p></trans-abstract><kwd-group xml:lang="en"><kwd>rheumatoid arthritis</kwd><kwd>vitamin D</kwd><kwd>cholecalciferol</kwd><kwd>Disease activity score</kwd><kwd>DAS28</kwd><kwd>osteoporosis</kwd><kwd>sarcopenia</kwd><kwd>obesity</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>ревматоидный артрит</kwd><kwd>витамин D</kwd><kwd>колекальциферол</kwd><kwd>DAS284</kwd><kwd>саркопения</kwd><kwd>ожирение</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Cutolo M, Otsa K, Uprus M, et al. Vitamin D in rheumatoid arthritis. Autoimmun Rev. 2007;7(1):59-64. DOI:10.1016/j.autrev.2007.07.001</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Rosen CJ, Adams JS, Bikle DD, et al. The nonskeletal effects of vitamin D: an Endocrine Society scientific statement. Endocr Rev. 2012;33(3):456-92. DOI:10.1210/er.2012-1000</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Cantorna MT. Vitamin D and autoimmunity: is vitamin D status an environmental factor affecting autoimmune disease prevalence? Proc Soc Exp Biol Med. 2000;223(3):230-3. DOI:10.1046/j.1525-1373.2000.22333.x</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Tetlow LC, Smith SJ, Mawer EB, Woolley DE. Vitamin D receptors in the rheumatoid lesion: expression by chondrocytes, macrophages, and synoviocytes. Ann Rheum Dis. 1999;58(2):118-21. DOI:10.1136/ard.58.2.118</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>van Hamburg JP, Asmawidjaja PS, Davelaar N, et al. TNF blockade requires 1,25(OH)2D3 to control human Th17-mediated synovial inflammation. Ann Rheum Dis. 2012;71(4):606-12. DOI:10.1136/annrheumdis-2011-200424</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Ranganathan P, Khalatbari S, Yalavarthi S, et al. Vitamin D deficiency, interleukin 17, and vascular function in rheumatoid arthritis. J Rheumatol. 2013;40(9):1529-34. DOI:10.3899/jrheum.130012</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Vojinovic J, Tincani A, Sulli A, et al. European multicenter pilot survey to assess vitamin D status in rheumatoid arthritis patients and early development of a new Patient Reported Outcome questionnaire (D-PRO). Autoimmun Rev. 2017;16(5):548-54. DOI:10.1016/j.autrev.2017.03.002</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Cutolo M, Otsa K, Laas K, et al. Circannual vitamin d serum levels and disease activity in rheumatoid arthritis: Northern versus Southern Europe. Clin Exp Rheumatol. 2006;24(6):702-4. PMID: 17207389</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Polasik K, Piotrowska E, Lipińska B, et al. Vitamin D status in patients with rheumatoid arthritis: a correlation analysis with disease activity and progression, as well as serum IL-6 levels. Acta Biochim Pol. 2017;64(4):667-70. DOI:10.18388/abp.2017_1636</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Furuya T, Hosoi T, Tanaka E, et al. Prevalence of and factors associated with vitamin D deficiency in 4,793 Japanese patients with rheumatoid arthritis. Clin Rheumatol. 2013;32(7):1081-7. DOI:10.1007/s10067-013-2216-4</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Hong Q, Xu J, Xu S, et al. Associations between serum 25-hydroxyvitamin D and disease activity, inflammatory cytokines and bone loss in patients with rheumatoid arthritis. Rheumatology (Oxford). 2014;53:1994-2001. DOI:10.1093/rheumatology/keu173</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Turhanoflu AD, Güler H, Yönden Z, et al. The relationship between vitamin D and disease activity and functional health status in rheumatoid arthritis. Rheumatol Int. 2011; 31:911-4. DOI:10.1007/s00296-010-1393-6</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Sahebari M, Mirfeizi Z, Rezaieyazdi Z, et al. 25(OH) vitamin D serum values and rheumatoid arthritis disease activity (DA S28 ESR), a cross-sectional study. Caspian J Intern Med. 2014;5(3):148-55</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Braun-Muscovici Y, Toledano K, Markovits D, et al. Vitamin D level: is it related to disease activity in inflammatory joint disease? Rheumatol Int. 2011;31:493-9. DOI:10.1007/s00296-009-1251-6</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Gopinath K, Danda D. Supplementation of 1,25- dihydroxyvitamin D3 in patients with treatment naive early rheumatoid arthritis: a randomized controlled trial. Int J Rheum Dis. 2011;14:332-9. DOI:10.1111/j.1756-185X.2011.01684.x</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Salesi M, Farajzadegan Z. Efficacy of vitamin D in patients with active rheumatoid arthritis receiving methotrexate therapy. Rheumatol Int. 2012;32:2129-33. DOI:10.1007/s00296-011-1944-5</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Остеопороз. Руководство для врачей. Под ред. О.М. Лесняк. M.: ГЭОТАР, 2016 [Osteoporosis. A guide for doctors. Ed. OM Lesnyak. Moscow: GEOTAR, 2016 (in Russian)].</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357(3):266-81. DOI:10.1056/NEJMra070553</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Heaney RP, Davies KM, Chen TC, et al. Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am J Clin Nutr. 2003;77(1):204-10. DOI:10.1093/ajcn/77.1.204</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Добровольская О.В., Демин Н.В., Смирнов А.В., и др. Состояние минеральной плотности кости у пациентов с системной склеродермией. Современная ревматология. 2019;13(1):58-63 [Dobrovolskaya OV, Demin NV, Smirnov AV, et al. Bone mineral density in patients with systemic scleroderma. Modern Rheumatology Journal. 2019;13(1):58-63 (in Russian)]. DOI:10.14412/1996-7012-2019-1-58-63</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Azzeh FS, Kensara OA. Vitamin D is a good marker for disease activity of rheumatoid arthritis disease. Dis Markers. 2015; 2015: 260725. DOI:10.1155/2015/260725</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Karahan I, Aras S, Varli M, et al. The frequency of sarcopenia and associated factors in older patients with rheumatoid arthritis. Eur J Geriatr Gerontol. 2020;2(2):41-5. DOI: 10.4274/ejgg.galenos.2020.314</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Haque UJ, Bartlett SJ. Relationships among vitamin D, disease activity, pain and disability in rheumatoid arthritis. Clin Exp Rheumatol. 2010;28(5):745-7. PMID: 20883640.</mixed-citation></ref></ref-list></back></article>
